OCGN - Ocugen, Inc. Stock Price and Quote

OCGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	0.40%	Shs Outstand	216.59M	Perf Week	0.79%
Market Cap	262.70M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	-29.26%	Shs Float	215.47M	Perf Month	-2.31%
Income	-74.00M	PEG	-	EPS next Q	-0.10	Inst Own	37.90%	Short Float / Ratio	20.70% / 8.70	Perf Quarter	-26.16%
Sales	-	P/S	-	EPS this Y	2.30%	Inst Trans	-3.59%	Short Interest	44.59M	Perf Half Y	-51.53%
Book/sh	0.44	P/B	2.89	EPS next Y	5.40%	ROA	-59.90%	Target Price	5.33	Perf Year	-64.23%
Cash/sh	0.49	P/C	2.59	EPS next 5Y	-	ROE	-67.80%	52W Range	1.09 - 4.53	Perf YTD	-2.31%
Dividend	-	P/FCF	-	EPS past 5Y	65.20%	ROI	-	52W High	-71.96%	Beta	3.90
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	-	Gross Margin	-	52W Low	16.51%	ATR	0.09
Employees	56	Current Ratio	7.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.02	Volatility	6.16% 7.05%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-87.10%	Profit Margin	-	Rel Volume	1.11	Prev Close	1.27
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 08 BMO	Payout	-	Avg Volume	5.12M	Price	1.27
Recom	2.20	SMA20	0.99%	SMA50	-6.63%	SMA200	-36.99%	Volume	5,672,109	Change	0.00%

Aug-23-22

Initiated

Mizuho

Buy

Jun-15-22

Resumed

ROTH Capital

Buy

Jun-02-22

Initiated

Cantor Fitzgerald

Overweight

$4.50

Jul-26-21

Initiated

Noble Capital Markets

Outperform

Jun-11-21

Downgrade

ROTH Capital

Buy → Neutral

$10 → $6

May-07-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-09-21

Downgrade

Chardan Capital Markets

Buy → Neutral

$0.70 → $13

Feb-04-21

Upgrade

H.C. Wainwright

Neutral → Buy

$4.50

Feb-01-23 08:00AM	Ocugen Appoints Quan A. Vu as Chief Business Officer GlobeNewswire
Jan-31-23 08:00AM	Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference GlobeNewswire
Jan-29-23 07:00AM	2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague Motley Fool
Jan-26-23 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2023 Motley Fool
Jan-23-23 05:21AM	3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street Motley Fool
07:03AM	Loading…
Jan-11-23 07:03AM	7 Loser Stocks to Short for Big Profits InvestorPlace
Jan-09-23 08:33AM	Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study Benzinga
06:22AM	UPDATE 2-Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial Reuters
06:16AM	Ocugen stock up 16% premarket after company announced positive results for its COVID vaccine MarketWatch
06:00AM	Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met GlobeNewswire
Dec-29-22 03:39PM	Why Shares of Ocugen Jumped Thursday Motley Fool +11.50%
Dec-25-22 03:58PM	7 Hot Meme Stocks of 2022 to Sell Before 2023 InvestorPlace
Dec-16-22 06:30AM	Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart® GlobeNewswire +5.52%
Dec-15-22 05:15PM	Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis GlobeNewswire -8.81%
Dec-13-22 08:00AM	Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell GlobeNewswire +5.44%
08:00AM	Loading…
Dec-07-22 08:00AM	Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis GlobeNewswire
Nov-28-22 07:30AM	Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit GlobeNewswire
Nov-17-22 09:23AM	3 Stocks to Avoid Right Now Motley Fool
Nov-09-22 06:16PM	Why Ocugen Stock Wilted on Wednesday Motley Fool -9.76%
Nov-08-22 06:30PM	Why Ocugen Stock Popped by 7% on Tuesday Motley Fool +7.19%
01:00PM	Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript Motley Fool
07:30AM	Ocugen Provides Business Update & Third Quarter 2022 Financial Results GlobeNewswire
Nov-07-22 08:17AM	Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40% Simply Wall St.
Nov-02-22 05:21AM	3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street Motley Fool -6.47%
Nov-01-22 07:42PM	Warning! Dont Even Consider Buying These 7 Dead-Money Stocks InvestorPlace
Oct-27-22 07:30AM	Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results GlobeNewswire -5.11%
Oct-19-22 07:30AM	Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 GlobeNewswire
Oct-12-22 05:37PM	Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 GlobeNewswire
Oct-06-22 09:25AM	Wall Street Thinks This Top 100 Robinhood Stock Could Skyrocket by 217% Motley Fool
08:00AM	Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences GlobeNewswire
07:30AM	Loading…
Sep-29-22 07:30AM	Ocugen, Inc. to Present at Chardans 6th Annual Genetic Medicines Conference GlobeNewswire -11.33%
Sep-28-22 12:28PM	Ocugen obtains exclusive license for nasal Covid-19 vaccine to complement Covaxin American City Business Journals +11.54%
09:44AM	Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine Benzinga
06:30AM	Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan GlobeNewswire
Sep-16-22 05:07PM	Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.05%
Sep-14-22 06:30AM	Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology GlobeNewswire
Sep-08-22 07:30AM	Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference GlobeNewswire
Sep-06-22 07:30AM	Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference GlobeNewswire -7.92%
Sep-01-22 06:28PM	Why Ocugen Stock Topped the Market Today Motley Fool
07:30AM	Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer GlobeNewswire
Aug-24-22 03:36PM	Why Ocugen Stock Is Racing Higher Today Motley Fool +12.50%
Aug-23-22 09:08AM	This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says Benzinga +9.40%
Aug-13-22 09:45AM	Here's How This Beaten-Down Stock Could 10X by 2024 Motley Fool
Aug-12-22 10:30AM	1 Robinhood Stock to Avoid Right Now Motley Fool +5.97%
07:30AM	Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference GlobeNewswire
Aug-06-22 05:31AM	Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript Motley Fool
Aug-05-22 07:30AM	Ocugen Provides Business Update & Second Quarter 2022 Financial Results GlobeNewswire
Aug-03-22 05:06PM	Ocugen Q2 Preview: Rebound Quarter Inbound? Zacks
Jul-29-22 03:27PM	Analysts Expect Breakeven For Ocugen, Inc. (NASDAQ:OCGN) Before Long Simply Wall St.
07:30AM	Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results GlobeNewswire
Jul-14-22 12:30PM	Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today Motley Fool -9.62%
Jul-13-22 12:25PM	Why Ocugen Is Climbing Today Motley Fool +5.82%
Jul-12-22 11:20AM	Why Ocugen Stock Is Sinking Today Motley Fool
Jul-08-22 04:48PM	Why Ocugen Stock Ascended Today Motley Fool +13.14%
Jun-21-22 12:47PM	Ocugen's efforts to bring Covid-19 vaccine Covaxin to U.S. boosted by positive study results in children American City Business Journals
10:22AM	Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years Benzinga
09:31AM	Twitter Accounts Hyped Company Seeking Covid Vaccine Trials Bloomberg
07:00AM	Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases GlobeNewswire
Jun-15-22 05:56AM	7 Stocks to Short Before July 2022 InvestorPlace +7.22%
Jun-14-22 07:00AM	Ocugen Named Among Philadelphias 2022 Best Places to Work GlobeNewswire
Jun-13-22 07:00AM	Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy GlobeNewswire -8.76%
Jun-10-22 06:39PM	Why Ocugen Stock Flopped on Friday Motley Fool
Jun-09-22 06:17PM	Ocugen, Inc. to Present at BIO International Convention 2022 GlobeNewswire -8.10%
Jun-07-22 07:29AM	Implied Volatility Surging for Ocugen (OCGN) Stock Options Zacks +12.16%
May-31-22 01:56PM	Ocugen adds regenerative medicines to its product pipeline American City Business Journals
May-30-22 12:53PM	How Much Of Ocugen, Inc. (NASDAQ:OCGN) Do Institutions Own? Simply Wall St.
May-28-22 06:30AM	Will This Beaten-Down Stock Bounce Back? 3 Things to Know Motley Fool
May-26-22 11:07AM	2 Struggling Stocks That Aren't Likely to Recover Anytime Soon Motley Fool
May-24-22 11:30AM	Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA Zacks -5.02%
09:30AM	Ocugen Diversifies Its Pipeline With New Cell Therapy Platform Benzinga
07:11AM	Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition GlobeNewswire
May-23-22 10:11AM	Philadelphia reinstates face-mask mandate for students and teachers, and WHO head warns pandemic is most certainly not over MarketWatch
08:53AM	FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial Benzinga
07:34AM	Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
07:28AM	U.S. drug regulator lifts clinical hold on Ocugen's COVID vaccine trial Reuters
06:50AM	Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidate MarketWatch
06:36AM	Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN (BBV152) GlobeNewswire
May-18-22 06:30AM	Is Ocugen Finally on the Way to Vaccine Revenue? Motley Fool -7.21%
May-13-22 07:10AM	Where Will Ocugen Be in 1 Year? Motley Fool +9.95%
May-06-22 12:30PM	Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript Motley Fool -5.26%
07:45AM	Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:33AM	Ocugen Provides Business Update and First Quarter 2022 Financial Results GlobeNewswire
May-02-22 07:37AM	Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results GlobeNewswire +6.85%
Apr-30-22 11:15AM	2 Small-Cap Stocks With Monster Upsides, According to Wall Street Motley Fool
Apr-29-22 11:36AM	Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting GlobeNewswire
Apr-28-22 11:00AM	Is It Too Late to Buy Ocugen Stock? Motley Fool
09:45AM	The Top Reasons to Avoid the Ocugen Stock InvestorPlace
09:05AM	The FDA Just Sent Ocugen a Warning. Should Investors Care? Motley Fool
Apr-27-22 05:06AM	3 Moonshot Stocks With Upside of Up to 709%, According to Wall Street Motley Fool
Apr-25-22 07:33AM	Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial GlobeNewswire
Apr-19-22 05:32PM	Ocugen, Inc. to Present at NobleCon18 GlobeNewswire
05:21AM	4 Ultra-Popular Stocks to Avoid Like the Plague Motley Fool
Apr-18-22 07:25PM	Why Ocugen Stock Tumbled by Nearly 6% Today Motley Fool -5.80%
09:30AM	Ocugen gets rights to Mexico in expanded Covaxin deal with Bharat Biotech American City Business Journals
07:11AM	Ocugen, Inc. to Commercialize COVAXIN in Mexico, Rights Now Encompassing All of North America GlobeNewswire
Apr-17-22 11:30AM	2 Red Flags for Ocugen's Future Motley Fool
Apr-14-22 01:34PM	Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More Zacks -7.07%
Apr-13-22 09:55AM	Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study Zacks +6.45%
Apr-12-22 10:00AM	Ocugen's study of Covid-19 vaccine Covaxin put on hold in wake of WHO inspection of Bharat American City Business Journals
09:28AM	FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial Benzinga

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Musunuri Shankar	Chief Executive Officer	Jan 17	Option Exercise	0.51	100,000	51,000	2,327,950	Jan 19 04:12 PM
Musunuri Shankar	Chief Executive Officer	Jan 17	Sale	1.28	100,000	128,000	2,227,950	Jan 19 04:12 PM
Musunuri Shankar	Chief Executive Officer	Dec 16	Option Exercise	0.51	95,809	48,863	848,349	Dec 20 04:07 PM
Musunuri Shankar	Chief Executive Officer	Dec 16	Sale	1.43	95,809	137,007	752,540	Dec 20 04:07 PM
Musunuri Shankar	Chief Executive Officer	Oct 14	Option Exercise	0.51	100,000	51,000	852,540	Oct 14 04:15 PM
Musunuri Shankar	Chief Executive Officer	Oct 14	Sale	1.66	100,000	166,000	752,540	Oct 14 04:15 PM
Kumar Ramesh	Director	Oct 06	Option Exercise	0.51	4,500	2,295	4,500	Oct 07 04:06 PM
Kumar Ramesh	Director	Oct 06	Sale	1.83	4,500	8,235	0	Oct 07 04:06 PM
Castillo Kirsten	Director	Aug 11	Option Exercise	0.28	42,000	11,760	92,000	Aug 12 04:49 PM
Castillo Kirsten	Director	Aug 11	Sale	2.91	42,000	122,220	50,000	Aug 12 04:49 PM
Kumar Ramesh	Director	Jul 18	Option Exercise	0.51	7,500	3,825	7,500	Jul 20 04:19 PM
Kumar Ramesh	Director	Jul 18	Sale	2.57	7,500	19,275	0	Jul 20 04:19 PM
Musunuri Shankar	Chief Executive Officer	Jul 14	Option Exercise	0.33	150,000	49,500	902,540	Jul 15 04:03 PM
Musunuri Shankar	Chief Executive Officer	Jul 14	Sale	2.72	150,000	408,000	752,540	Jul 15 04:03 PM
Musunuri Shankar	Chief Executive Officer	May 13	Option Exercise	0.33	125,000	41,250	877,540	May 13 04:02 PM
Musunuri Shankar	Chief Executive Officer	May 13	Sale	1.92	125,000	240,000	752,540	May 13 04:02 PM
Kumar Ramesh	Director	Apr 18	Option Exercise	0.51	7,500	3,825	7,500	Apr 20 04:03 PM
Kumar Ramesh	Director	Apr 18	Sale	2.83	7,500	21,225	0	Apr 20 04:03 PM
Musunuri Shankar	Chief Executive Officer	Mar 16	Option Exercise	0.33	81,823	27,002	834,363	Mar 18 04:03 PM
Musunuri Shankar	Chief Executive Officer	Mar 16	Sale	2.65	81,823	216,831	752,540	Mar 18 04:03 PM
Zhang Junge	Director	Mar 03	Option Exercise	1.25	88,000	109,560	88,000	Mar 04 04:03 PM
Musunuri Shankar	Chief Executive Officer	Feb 14	Option Exercise	0.33	90,000	29,700	842,540	Feb 16 04:03 PM
Musunuri Shankar	Chief Executive Officer	Feb 14	Sale	3.74	90,000	336,600	752,540	Feb 16 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience